|
| 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Basic information |
Product Name: | 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- | Synonyms: | 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-;LXR623;2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole;WAY 252623;2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-;2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole WAY 252623;LXR623/LXR-623;2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole | CAS: | 875787-07-8 | MF: | C21H12ClF5N2 | MW: | 422.78 | EINECS: | | Product Categories: | Inhibitor;Inhibitors;API | Mol File: | 875787-07-8.mol | |
| 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Chemical Properties |
Melting point | 93℃ | Boiling point | 528.4±50.0 °C(Predicted) | density | 1.40 | storage temp. | room temp | solubility | DMSO:50.0(Max Conc. mg/mL);118.26(Max Conc. mM) Ethanol:52.0(Max Conc. mg/mL);123.0(Max Conc. mM) | pka | -1.87±0.30(Predicted) | form | powder | color | white to beige |
RIDADR | UN 2811 6.1 / PGIII |
| 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Usage And Synthesis |
Uses | WAY 252623 is a novel and potent LXR (liverX receptor) β-agonist used as a potential candidate for the treatment of atopic dermatitis. | Biochem/physiol Actions | WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model. | storage | Store at +4°C |
| 2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- Preparation Products And Raw materials |
|